Lymphoma and Chronic Lymphocytic Leukemias 2016:6 13-19
Review
Published on 12 Jun 2016
DOI: 10.4137/LCLL.S34946
Sign up for email alerts to receive notifications of new articles published in Lymphoma and Chronic Lymphocytic Leukemias
Posttransplant lymphoproliferative disorders (PTLDs) are defined by the 2008 World Health Organization classification. Monomorphic PTLD is the most frequent form; it is usually diagnosed several years after transplantation and nowadays is positive for Epstein–Barr virus in only 50% of cases. Although preventive treatments are not effective, in cases of Epstein–Barr virus reactivation, a preemptive approach can prevent the development of PTLD. The first-line curative treatment consists of reducing immunosuppression, where possible, and this alone can cure PTLD. If this fails, rituximab monotherapy is safe and induces complete remission in one-third of cases. If complete remission is not achieved, four cycles of R-CHOP [cyclophosphamide, hydroxy doxorubicin, vincristine (Oncovin®), and prednisone plus rituximab] are generally sufficient.
PDF (1022.32 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Facebook Twitter
Pinterest